EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells

Ritis Kumar Shyanti, Mazharul Haque, Rajesh Singh, Manoj Mishra

Clinical Immunology · 2024-12 · 269 · 110402

DOI: 10.1016/j.clim.2024.110402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Immunology, 2024-12. Verfasst von Ritis Kumar Shyanti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA. Hauptthemen laut MEDLINE: Antigens, CD1d, Natural Killer T-Cells, Neoplasms, Antigen-Presenting Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, National Science Foundation, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two major antigen processing pathways represent protein Ags through major histocompatibility complexes (MHC class I and II) or lipid Ags through CD1 molecules influence the tumor immune response. Invariant Natural Killer T cells (iNKT) manage a significant role in cancer immunotherapy. CD1d, found on antigen-presenting cells (APCs), presents lipid Ags to iNKT cells. In many cancers, the number and function of iNKT cell are compromised, leading to immune evasion. Additionally impaired motility of iNKT cells may contribute to poor tumor prognosis. Emerging evidences suggest that CD1d, itself also influences cancer progression. Patient databases further highlight the importance of CD1d expression in different cancers and its correlation with patient survival outcomes. The ability of iNKT cells to activate and enhance the immune response renders them an attractive target for cancer immunotherapy. This review discusses all the possible ways of cancer immune evasion and restoration of immune responses mediated by CD1d-iNKT interactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD1dNatural Killer T-CellsNeoplasmsAntigen-Presenting CellsHumansAnimalsImmunotherapyAntigen Presentation

Stichwörter der Autor:innen

CD1dCytokinesInvariant natural killer T cellsLipid antigensTumor immunity

Substanzen

Antigens, CD1dCD1D protein, human

Autor:innen und Institutionen

  • Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA.
  • Microbiology, Biochemistry, and Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA, USA.
  • Cancer Research Center, Department of Biological Sciences, Alabama State University, AL 36104, USA. Electronic address: mmishra@alasu.edu.

Förderung

  • NIA NIH HHS
  • National Science Foundation
  • National Institutes of Health
  • American Cancer Society
  • Foundation for the National Institutes of Health

Zitieren

APA

Shyanti, R. K., Haque, M., Singh, R., & Mishra, M. (2024). Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells. Clinical Immunology, 269, 110402. https://doi.org/10.1016/j.clim.2024.110402

Vancouver

Shyanti RK, Haque M, Singh R, Mishra M. Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells. Clinical Immunology. 2024;269:110402. doi:10.1016/j.clim.2024.110402

BibTeX
@article{Shyanti2024,
  author = {Shyanti, Ritis Kumar and Haque, Mazharul and Singh, Rajesh and Mishra, Manoj},
  title = {Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells},
  journal = {Clinical Immunology},
  year = {2024},
  volume = {269},
  pages = {110402},
  doi = {10.1016/j.clim.2024.110402}
}
Kostenlos starten →